Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022

Euro Surveill. 2023 Feb;28(8):2300105. doi: 10.2807/1560-7917.ES.2023.28.8.2300105.

Abstract

Effectiveness against severe COVID-19 of a second booster dose of the bivalent (original/BA.4-5) mRNA vaccine 7-90 days post-administration, relative to a first booster dose of an mRNA vaccine received ≥ 120 days earlier, was ca 60% both in persons ≥ 60 years never infected and in those infected > 6 months before. Relative effectiveness in those infected 4-6 months earlier indicated no significant additional protection (10%; 95% CI: -44 to 44). A second booster vaccination 6 months after the latest infection may be warranted.

Keywords: COVID-19; Italy; SARS-CoV-2; bivalent mRNA vaccines; effectiveness; elderly population.

MeSH terms

  • COVID-19* / prevention & control
  • Humans
  • Italy / epidemiology
  • RNA, Messenger
  • Vaccination
  • mRNA Vaccines

Substances

  • RNA, Messenger